In addition, we investigated the ability of the CCRGPI to predict the prognosis of patients receiving ICI therapy using the immunotherapy datasets of HNSCC (GSE212550, anti-PD-1) and uroepithelial cancer (IMvigor210, anti-PD-L1). Here, CD274 is linked to head and neck squamous cell carcinoma.